Novo Nordisk
Danish pharmaceutical company
Follow Novo Nordisk on Notably News to receive short updates to your email — rarely!
| May 10 2025 | As of this date, Novo Holdings A/S remains the largest shareholder of Novo Nordisk, owning 28.1% of the company's shares. |
| March 2025 | Established NovoCare, a new pharmacy offering direct-to-consumer Wegovy at $499 per month, significantly reducing the drug's typical distribution cost. |
| 2024 | Novo Nordisk acquired Catalent, marking a significant expansion of its pharmaceutical manufacturing and development resources. |
| October 2024 | Novo Nordisk published a study in the scientific journal Nature about a novel glucose-sensitive insulin NNC2215 that demonstrates potential to reduce hypoglycemia risk in animal models. |
| September 2024 | CEO Lars Fruergaard Jørgensen was summoned to testify before the US Senate Health, Education, Labor and Pensions Committee, where Senator Bernie Sanders told him to 'Stop Ripping Us Off' regarding drug pricing. |
| July 2024 | US President Joe Biden joined Senator Bernie Sanders in criticizing Novo Nordisk for high drug prices, specifically highlighting Ozempic and Wegovy's significantly higher US pricing compared to other countries. |
| June 2024 | Novo Nordisk announced plans to build a new $4.1 billion production plant in Clayton, North Carolina, for manufacturing semaglutide products Ozempic and Wegovy. |
| May 2024 | Novo Nordisk announced acquisition of Austrian fluid management service business, Single Use Support. |
| March 2024 | Novo Nordisk reached $604 billion market capitalization, becoming the 12th most valuable company globally. The company announced acquisition of Cardior Pharmaceuticals for up to $1.1 billion and showed positive early trial data for experimental weight loss pill amycretin. |
| February 2024 | Novo Holdings A/S agreed to acquire Catalent for $16.5 billion, with Novo Nordisk planning to acquire three manufacturing facilities for $11 billion to scale up production of Wegovy and Ozempic. |
| February 2 2024 | United States Judicial Panel consolidated 55 lawsuits into multidistrict litigation (MDL No. 3094) regarding Ozempic, with 235 active lawsuits alleging gastroparesis and other injuries. |
| 2023 | Novo Nordisk's market capitalization exceeded the GDP of Denmark's domestic economy, becoming the highest valued company in Europe. |
| November 2023 | Novo Nordisk announced a €2.1 billion investment in a French production facility to increase manufacturing of anti-obesity medication. |
| October 2023 | Novo Nordisk announced acquisition of ocedurenone from KBP Biosciences for $1.3 billion, an experimental drug for uncontrolled hypertension. |
| September 2023 | Novo Nordisk and UNICEF announced a multi-year collaboration to address childhood overweight and obesity. |
| August 2023 | Novo Nordisk agreed to acquire Montreal-headquartered Inversago Pharma for $1 billion and Embark Biotech for up to $500 million. |
| March 2023 | Suspended from the ABPI for two years for misleading marketing practices. UK professional medical colleges ended corporate partnerships, and UK General Manager Pinder Sahota resigned as ABPI President. |
| September 2022 | Novo Nordisk agreed to acquire Forma Therapeutics for $1.1 billion to expand its sickle cell disease and rare blood disorders portfolio. |
| 2021 | Novo Nordisk acquired Dicerna Pharmaceuticals, Rheincell Therapeutics, and Bettera Holdings LLC, further diversifying its pharmaceutical and biotechnology capabilities. |
| November 2021 | Novo Nordisk announced acquisition of Dicerna Pharmaceuticals and its RNAi therapeutics for $3.3 billion. |
| 2020 | Novo Nordisk acquired multiple companies including Corvidia Therapeutics, Emisphere Technologies, and MaSTherCell, significantly expanding its research and development portfolio. |
| November 2020 | Novo Nordisk announced acquisition of Emisphere Technologies for $1.8 billion to gain control of a pill-based diabetes treatment. |
| June 2020 | Announced acquisition of AstraZeneca's Corvidia Therapeutics for an initial $725 million, with potential performance-related maximum of $2.1 billion. |
| June 2020 | Novo Nordisk announced acquisition of Corvidia Therapeutics for an initial $725 million, with potential performance-related increase up to $2.1 billion, to boost cardiovascular disease presence. |
| March 2020 | Novo Nordisk volunteers began testing SARS-CoV-2 samples using RT-qPCR equipment to increase pandemic testing capacity. |
| 2019 | Novo Nordisk acquired Paragon Bioservices Inc, expanding its biopharmaceutical development and manufacturing capabilities. |
| 2018 | The company announced the acquisition of Ziylo for around $800 million, further expanding its business interests. |
| September 2018 | Novo Nordisk decided to lay off 400 administrative staff, laboratory technicians, and scientists in Denmark and China to focus research and development efforts on transformational biological and technological innovation. |
| January 2018 | Novo Nordisk attempted to acquire Ablynx for $3.1 billion, but the Ablynx board rejected the offer as undervaluing the business. |
| 2017 | Novo Nordisk was ranked 73rd on Fortune's 100 Best Companies to Work For list. |
| 2017 | Novo Nordisk acquired Cook Pharmica, increasing its manufacturing and development capabilities. |
| September 2017 | Agreed to pay $58.7 million to resolve a US Department of Justice probe into lack of FDA disclosure about cancer risks for the diabetic drug Victoza. |
| 2016 | Novo Nordisk acquired Pharmatek Laboratories, expanding its research and development infrastructure. |
| 2015 | The company announced a collaboration with Ablynx to develop at least one new drug candidate using Ablynx's nanobody technology. |
| March 2015 | NNIT was floated on the Nasdaq Nordic stock exchange. |
| 2014 | Novo Nordisk was ranked 72nd on Fortune's 100 Best Companies to Work For list. |
| 2014 | Novo Nordisk acquired Micron Technologies, enhancing its technological resources. |
| November 2014 | Following a potential medical research breakthrough at Harvard University involving insulin-producing cells from embryonic stem cells, Novo Nordisk's chief medical officer Dr. Alan Moses commented on the complexity of diabetes and the company's mission to alleviate and cure the disease. |
| September 2014 | Novo Nordisk announced the discontinuation of all research in inflammatory disorders, including halting R&D on anti-IL-20 for rheumatoid arthritis treatment. |
| March 2014 | Novo Nordisk launched the 'Cities Changing Diabetes' partnership program to combat urban diabetes, collaborating with University College London (UCL), Steno Diabetes Center, and various local partners including healthcare professionals, city authorities, urban planners, businesses, academics, and community leaders. |
| 2013 | Novo Nordisk USA relocated to new headquarters in Plainsboro Township, New Jersey, consolidating multiple previous facilities through extensive renovation of abandoned premises. |
| 2013 | Novo Nordisk acquired Xellia pharmaceutical company for $700 million, expanding its business portfolio. |
| October 2013 | Recalled batches of NovoMix 30 FlexPen and Penfill insulin in some European countries due to some products not meeting insulin strength specifications. |
| March 2013 | Scientists debated potential increased risk of pancreatic side effects for the incretin class of diabetic medications, including Victoza, ultimately concluding that available data did not confirm these concerns. |
| 2012 | Novo Nordisk acquired Aptuit, expanding its pharmaceutical development capabilities. |
| 2012 | A follow-up to the DAWN study was completed, involving more than 15,000 people living with or caring for those with diabetes, further expanding research into the psychosocial aspects of diabetes care. |
| January 2012 | Novo Nordisk was named the most sustainable company in the world by Corporate Knights business magazine. |
| 2010 | Novo Nordisk breached the Association of the British Pharmaceutical Industry (ABPI) code of conduct by failing to provide information about side-effects of Victoza and promoting the drug prior to market authorization. |
| 2010 | Novo Nordisk was ranked 25th on Fortune's 100 Best Companies to Work For list. |
This contents of the box above is based on material from the Wikipedia article Novo Nordisk, which is released under the Creative Commons Attribution-ShareAlike 4.0 International License.